GenSight Biologics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
GenSight Biologics has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 13.6% per year.
Anahtar bilgiler
6.7%
Kazanç büyüme oranı
22.1%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 30.8% |
| Gelir büyüme oranı | -13.6% |
| Özkaynak getirisi | n/a |
| Net Marj | -1,017.5% |
| Sonraki Kazanç Güncellemesi | 23 Jan 2025 |
Yakın geçmiş performans güncellemeleri
Recent updates
Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?
Dec 22
Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?
Sep 20Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?
Aug 17Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt
Aug 04GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 14GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?
May 10Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long
Feb 02A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary
Dec 09
Gelir ve Gider Dağılımı
GenSight Biologics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -20 | 8 | 14 |
| 31 Mar 24 | 2 | -23 | 11 | 17 |
| 31 Dec 23 | 3 | -26 | 13 | 19 |
| 30 Sep 23 | 3 | -28 | 14 | 20 |
| 30 Jun 23 | 3 | -29 | 15 | 21 |
| 31 Mar 23 | 4 | -28 | 14 | 20 |
| 31 Dec 22 | 5 | -28 | 13 | 19 |
| 30 Sep 22 | 5 | -29 | 14 | 22 |
| 30 Jun 22 | 5 | -31 | 14 | 25 |
| 31 Mar 22 | 6 | -30 | 13 | 24 |
| 31 Dec 21 | 8 | -29 | 13 | 23 |
| 30 Sep 21 | 9 | -28 | 12 | 21 |
| 30 Jun 21 | 11 | -28 | 11 | 18 |
| 31 Mar 21 | 9 | -31 | 10 | 20 |
| 31 Dec 20 | 7 | -34 | 10 | 22 |
| 30 Sep 20 | 7 | -31 | 9 | 23 |
| 30 Jun 20 | 6 | -28 | 8 | 25 |
| 31 Mar 20 | 5 | -30 | 7 | 27 |
| 31 Dec 19 | 5 | -31 | 6 | 29 |
| 30 Sep 19 | 5 | -35 | 7 | 32 |
| 30 Jun 19 | 5 | -39 | 8 | 36 |
| 31 Mar 19 | 5 | -36 | 8 | 32 |
| 31 Dec 18 | 4 | -33 | 8 | 29 |
| 30 Sep 18 | 4 | -30 | 8 | 25 |
| 30 Jun 18 | 4 | -26 | 8 | 21 |
| 31 Mar 18 | 4 | -25 | 9 | 20 |
| 31 Dec 17 | 4 | -24 | 9 | 19 |
| 30 Sep 17 | 3 | -23 | 9 | 18 |
| 30 Jun 17 | 3 | -23 | 9 | 17 |
| 31 Mar 17 | 3 | -22 | 8 | 17 |
| 31 Dec 16 | 3 | -22 | 7 | 18 |
| 30 Sep 16 | 3 | -20 | 6 | 16 |
| 30 Jun 16 | 4 | -18 | 5 | 14 |
| 31 Mar 16 | 4 | -16 | 5 | 12 |
| 31 Dec 15 | 4 | -14 | 4 | 10 |
| 30 Sep 15 | 3 | -11 | 3 | 9 |
| 30 Jun 15 | 2 | -9 | 3 | 9 |
| 31 Mar 15 | 2 | -8 | 2 | 7 |
| 31 Dec 14 | 1 | -7 | 2 | 6 |
| 31 Dec 13 | 1 | -3 | 1 | 3 |
Kaliteli Kazançlar: SIGHT is currently unprofitable.
Büyüyen Kar Marjı: SIGHT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: SIGHT is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.
Büyüme Hızlandırma: Unable to compare SIGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: SIGHT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Özkaynak Getirisi
Yüksek ROE: SIGHT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.